These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

399 related articles for article (PubMed ID: 26343143)

  • 1. Escape, or Vanish: Control the Fate of p53 through MDM2-Mediated Ubiquitination.
    Wei J; Yang Y; Lu M; Xu L; Liu F; Yuan Z; Bao Q; Jiang Z; Xu X; Guo X; Zhang X; You Q; Sun H
    Anticancer Agents Med Chem; 2015; 16(2):174-89. PubMed ID: 26343143
    [TBL] [Abstract][Full Text] [Related]  

  • 2. RNF12 promotes p53-dependent cell growth suppression and apoptosis by targeting MDM2 for destruction.
    Gao K; Wang C; Jin X; Xiao J; Zhang E; Yang X; Wang D; Huang H; Yu L; Zhang P
    Cancer Lett; 2016 May; 375(1):133-141. PubMed ID: 26926424
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mdm2 RING mutation enhances p53 transcriptional activity and p53-p300 interaction.
    Clegg HV; Itahana Y; Itahana K; Ramalingam S; Zhang Y
    PLoS One; 2012; 7(5):e38212. PubMed ID: 22666487
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reactivation of p53 by inhibiting Mdm2 E3 ligase: a novel antitumor approach.
    Di J; Zhang Y; Zheng J
    Curr Cancer Drug Targets; 2011 Oct; 11(8):987-94. PubMed ID: 21762075
    [TBL] [Abstract][Full Text] [Related]  

  • 5. MDM2 E3 ligase activity is essential for p53 regulation and cell cycle integrity.
    Chinnam M; Xu C; Lama R; Zhang X; Cedeno CD; Wang Y; Stablewski AB; Goodrich DW; Wang X
    PLoS Genet; 2022 May; 18(5):e1010171. PubMed ID: 35588102
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Unlocking the Mdm2-p53 loop: ubiquitin is the key.
    Clegg HV; Itahana K; Zhang Y
    Cell Cycle; 2008 Feb; 7(3):287-92. PubMed ID: 18235222
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Smad ubiquitylation regulatory factor 1/2 (Smurf1/2) promotes p53 degradation by stabilizing the E3 ligase MDM2.
    Nie J; Xie P; Liu L; Xing G; Chang Z; Yin Y; Tian C; He F; Zhang L
    J Biol Chem; 2010 Jul; 285(30):22818-30. PubMed ID: 20484049
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Acetylation-dependent regulation of MDM2 E3 ligase activity dictates its oncogenic function.
    Nihira NT; Ogura K; Shimizu K; North BJ; Zhang J; Gao D; Inuzuka H; Wei W
    Sci Signal; 2017 Feb; 10(466):. PubMed ID: 28196907
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Regulation of Mdm2 protein stability and the p53 response by NEDD4-1 E3 ligase.
    Xu C; Fan CD; Wang X
    Oncogene; 2015 Jan; 34(3):281-9. PubMed ID: 24413081
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MDM2 acts downstream of p53 as an E3 ligase to promote FOXO ubiquitination and degradation.
    Fu W; Ma Q; Chen L; Li P; Zhang M; Ramamoorthy S; Nawaz Z; Shimojima T; Wang H; Yang Y; Shen Z; Zhang Y; Zhang X; Nicosia SV; Zhang Y; Pledger JW; Chen J; Bai W
    J Biol Chem; 2009 May; 284(21):13987-4000. PubMed ID: 19321440
    [TBL] [Abstract][Full Text] [Related]  

  • 11. TRIAD1 inhibits MDM2-mediated p53 ubiquitination and degradation.
    Bae S; Jung JH; Kim K; An IS; Kim SY; Lee JH; Park IC; Jin YW; Lee SJ; An S
    FEBS Lett; 2012 Sep; 586(19):3057-63. PubMed ID: 22819825
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The anaphase-promoting complex/cyclosome is an E3 ubiquitin ligase for Mdm2.
    He Y; Tollini L; Kim TH; Itahana Y; Zhang Y
    Cell Cycle; 2014; 13(13):2101-9. PubMed ID: 24804778
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Functional analysis and consequences of Mdm2 E3 ligase inhibition in human tumor cells.
    Wade M; Li YC; Matani AS; Braun SM; Milanesi F; Rodewald LW; Wahl GM
    Oncogene; 2012 Nov; 31(45):4789-97. PubMed ID: 22266850
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dual-site regulation of MDM2 E3-ubiquitin ligase activity.
    Wallace M; Worrall E; Pettersson S; Hupp TR; Ball KL
    Mol Cell; 2006 Jul; 23(2):251-63. PubMed ID: 16857591
    [TBL] [Abstract][Full Text] [Related]  

  • 15. TRIAD1 is negatively regulated by the MDM2 E3 ligase.
    Bae S; Jung JH; An IS; Kim OY; Lee MJ; Lee JH; Park IC; Lee SJ; An S
    Oncol Rep; 2012 Nov; 28(5):1924-8. PubMed ID: 22940738
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeted inactivation of Mdm2 RING finger E3 ubiquitin ligase activity in the mouse reveals mechanistic insights into p53 regulation.
    Itahana K; Mao H; Jin A; Itahana Y; Clegg HV; Lindström MS; Bhat KP; Godfrey VL; Evan GI; Zhang Y
    Cancer Cell; 2007 Oct; 12(4):355-66. PubMed ID: 17936560
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Overexpression of Mdm2 and MdmX fusion proteins alters p53 mediated transactivation, ubiquitination, and degradation.
    Ghosh M; Huang K; Berberich SJ
    Biochemistry; 2003 Mar; 42(8):2291-9. PubMed ID: 12600196
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mutant p53 Sequestration of the MDM2 Acidic Domain Inhibits E3 Ligase Activity.
    Yang L; Song T; Cheng Q; Chen L; Chen J
    Mol Cell Biol; 2019 Feb; 39(4):. PubMed ID: 30455251
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The regulation of MDM2 by multisite phosphorylation--opportunities for molecular-based intervention to target tumours?
    Meek DW; Hupp TR
    Semin Cancer Biol; 2010 Feb; 20(1):19-28. PubMed ID: 19897041
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Auto-ubiquitination of Mdm2 enhances its substrate ubiquitin ligase activity.
    Ranaweera RS; Yang X
    J Biol Chem; 2013 Jun; 288(26):18939-46. PubMed ID: 23671280
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.